Evercore ISI notes that Dentsply Sirona (XRAY) announced that it will be pivoting its approach to Byte to incorporate in-person dentist oversight and will not reinstate the At Home model, which the analyst says “seems logical” given that the broader DTC aligner market is struggling to gain traction. Management’s timely resolution adds some clarity around potential stranded costs, adds the analyst, who has an In Line rating and $20 price target on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRAY:
- DENTSPLY SIRONA Discusses Byte Strategy at Conference
- Dentsply Sirona to reposition Byte business within aligner portfolio
- Dentsply Sirona downgraded to In Line from Outperform at Evercore ISI
- Dentsply Sirona price target lowered to $23 from $30 at Morgan Stanley
- Shareholder Alert for Dentsply Sirona, Inc. (NASDAQ:XRAY)